We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Read MoreHide Full Article
Key Takeaways
CRL's RMS segment grew 6.5% in Q3 2025, led by Noveprim, China, CRADL, GEMS and aca/govt. clients.
CRL expands via partnerships with Elly's Team, Parker Institute, CHDI Foundation, Deciphex and Akron Bio.
CRL faces cautious biotech spending, NIH-dependent revenues, tariffs and competition across segments.
Charles River Laboratories International, Inc.’s (CRL - Free Report) solid prospects in the Research Models and Services (“RMS”) segment are supported by consistent demand for its research model services. The company expands the scope of its offerings across the drug discovery and early-stage development continuum through focused partnerships and acquisitions. Solid financial health is another advantage. However, macroeconomic impacts and fierce competitive pressures may pose operational risks for Charles River.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 7% compared with the industry’s 7.7% growth. Meanwhile, the S&P 500 composite has risen 18% during the same period.
The renowned, non-clinical global drug development company has a market capitalization of $9.61 billion. Charles River has an earnings yield of 5.2% compared with the industry’s 3.4% yield. It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 12.4%.
Let’s delve deeper.
Upsides for CRL Stock
RMS Prospects Seem Bright: Charles River continues to maintain its position as a global leader in the production and sale of the most widely used research models. In the third quarter of 2025, revenues increased 6.5% on an organic basis, driven by a surge in large research model product revenues, notably from Noveprim and within China. Revenues from both academic and government client segments also climbed, including a slight rise in North America.
Historically, the CRADL (Charles River Accelerator and Development Lab) service has been one of the largest growth drivers for RMS. However, of late, it has been impacted by the overall biopharma demand environment. Despite this, CRADL’s business model continues to resonate with clients to access flexible vivarium space without having to invest in internal infrastructure, offering a strong value proposition for those looking to reduce costs and conserve capital. Also, in the quarter, contributions from the GEMS business drove research model services revenues.
Image Source: Zacks Investment Research
Strategic Deals Drive Growth: During the third quarter of 2025, the company teamed up with Elly’s Team to support fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease. Another two strategic collaborations across its contract development and manufacturing organization (CDMO) — the Parker Institute for Cancer Immunotherapy and with Children’s Hospital Los Angeles — are aimed at advancing novel oncology research and development. This year, Charles River extended its multi-decade collaboration with CHDI Foundation to progress options for the treatment of Huntington’s disease and also Deciphex, the AI-powered digital pathology leader. Additionally, Charles River and Akron Bio collaborated to enhance operations with the integration of CGMP materials into the cell therapy platform.
Stable Solvency Structure: Charles River exited the third quarter of 2025 with cash and cash equivalents of $207 million, while short-term debt payable was nil. This is good news in terms of the company’s solvency position, particularly during the time of worldwide macroeconomic complications. Meanwhile, long-term debt dropped 6.3% sequentially, reaching $2.19 billion. The debt-to-capital ratio was 39.1% compared with 41% in the second quarter. The times interest ratio remained flat at 0.8%.
Factors Affecting Charles River
Macroeconomic Condition: Charles River is experiencing a cautious spending environment, particularly among its global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines and manage their cost structures. In the third quarter of 2025, revenues for small and mid-sized biotech clients declined, reflecting tighter budgets. Moreover, the RMS segment derives certain revenues from academic institutions and research laboratories that depend on funding from agencies like the U.S. National Institutes of Health (NIH).
Additionally, the company is exposed to a difficult operating environment, including heightened geopolitical pressure. Charles River is now subject to tariffs on imports from its major supplier countries such as Vietnam, Mauritius and China.
Competitive Landscape: Charles River competes in the marketplace on the basis of its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in each of its three business segments. This fiercely competitive global market impacts the company’s market capitalization scenario.
CRL Stock Estimate Trend
The Zacks Consensus Estimate for CRL’s 2025 earnings has increased 1 cent to $10.22 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $4.01 billion, suggesting a 1% decrease from the year-ago reported number.
BrightSpring Health Serviceshas an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 108.8% compared with the industry’s 7.6% growth in the past year. BTSG sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, sporting a Zacks Rank #1, has an earnings yield of 3.7% compared to the industry’s -17.9% yield. Shares of the company have dropped 3.3% in the past year against the industry’s 16.9% growth. ILMN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.7%.
Insulet, carrying a Zacks Rank #2 (Buy), has an earnings yield of 3.9% against the industry’s -0.9% yield. Shares of the company have increased 12.9% compared with the industry’s 1.9% growth. PODD’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Key Takeaways
Charles River Laboratories International, Inc.’s (CRL - Free Report) solid prospects in the Research Models and Services (“RMS”) segment are supported by consistent demand for its research model services. The company expands the scope of its offerings across the drug discovery and early-stage development continuum through focused partnerships and acquisitions. Solid financial health is another advantage. However, macroeconomic impacts and fierce competitive pressures may pose operational risks for Charles River.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 7% compared with the industry’s 7.7% growth. Meanwhile, the S&P 500 composite has risen 18% during the same period.
The renowned, non-clinical global drug development company has a market capitalization of $9.61 billion. Charles River has an earnings yield of 5.2% compared with the industry’s 3.4% yield. It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 12.4%.
Let’s delve deeper.
Upsides for CRL Stock
RMS Prospects Seem Bright: Charles River continues to maintain its position as a global leader in the production and sale of the most widely used research models. In the third quarter of 2025, revenues increased 6.5% on an organic basis, driven by a surge in large research model product revenues, notably from Noveprim and within China. Revenues from both academic and government client segments also climbed, including a slight rise in North America.
Historically, the CRADL (Charles River Accelerator and Development Lab) service has been one of the largest growth drivers for RMS. However, of late, it has been impacted by the overall biopharma demand environment. Despite this, CRADL’s business model continues to resonate with clients to access flexible vivarium space without having to invest in internal infrastructure, offering a strong value proposition for those looking to reduce costs and conserve capital. Also, in the quarter, contributions from the GEMS business drove research model services revenues.
Image Source: Zacks Investment Research
Strategic Deals Drive Growth: During the third quarter of 2025, the company teamed up with Elly’s Team to support fast-track production of therapeutic targeting ultra-rare neurodevelopmental disease. Another two strategic collaborations across its contract development and manufacturing organization (CDMO) — the Parker Institute for Cancer Immunotherapy and with Children’s Hospital Los Angeles — are aimed at advancing novel oncology research and development. This year, Charles River extended its multi-decade collaboration with CHDI Foundation to progress options for the treatment of Huntington’s disease and also Deciphex, the AI-powered digital pathology leader. Additionally, Charles River and Akron Bio collaborated to enhance operations with the integration of CGMP materials into the cell therapy platform.
Stable Solvency Structure: Charles River exited the third quarter of 2025 with cash and cash equivalents of $207 million, while short-term debt payable was nil. This is good news in terms of the company’s solvency position, particularly during the time of worldwide macroeconomic complications. Meanwhile, long-term debt dropped 6.3% sequentially, reaching $2.19 billion. The debt-to-capital ratio was 39.1% compared with 41% in the second quarter. The times interest ratio remained flat at 0.8%.
Factors Affecting Charles River
Macroeconomic Condition: Charles River is experiencing a cautious spending environment, particularly among its global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines and manage their cost structures. In the third quarter of 2025, revenues for small and mid-sized biotech clients declined, reflecting tighter budgets. Moreover, the RMS segment derives certain revenues from academic institutions and research laboratories that depend on funding from agencies like the U.S. National Institutes of Health (NIH).
Additionally, the company is exposed to a difficult operating environment, including heightened geopolitical pressure. Charles River is now subject to tariffs on imports from its major supplier countries such as Vietnam, Mauritius and China.
Competitive Landscape: Charles River competes in the marketplace on the basis of its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in each of its three business segments. This fiercely competitive global market impacts the company’s market capitalization scenario.
CRL Stock Estimate Trend
The Zacks Consensus Estimate for CRL’s 2025 earnings has increased 1 cent to $10.22 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $4.01 billion, suggesting a 1% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , lllumina (ILMN - Free Report) and Insulet (PODD - Free Report) .
BrightSpring Health Serviceshas an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 108.8% compared with the industry’s 7.6% growth in the past year. BTSG sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, sporting a Zacks Rank #1, has an earnings yield of 3.7% compared to the industry’s -17.9% yield. Shares of the company have dropped 3.3% in the past year against the industry’s 16.9% growth. ILMN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.7%.
Insulet, carrying a Zacks Rank #2 (Buy), has an earnings yield of 3.9% against the industry’s -0.9% yield. Shares of the company have increased 12.9% compared with the industry’s 1.9% growth. PODD’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.8%.